AstraZeneca doubles buyback as Brilinta shines
AstraZeneca doubled its 2010 share buyback program on Thursday, after posting strong results and winning an endorsement from a U.S. advisory panel for its potential blockbuster heart drug Brilinta.
Read more on Reuters via Yahoo! News
Glenmark gets USFDA’s tentative nod for Riluzone
Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals, today said it has received tentative approval from the USFDA for generic version of Sanofi Aventis’ neurological disease treatment drug Rilutek.
Read more on Business Standard India
Financial help for seniors
Senior citizens and others living on a fixed or low income know how difficult it is to make ends meet, especially when costs for essentials like health care, food and energy increase faster than their sources of income.
Read more on Messenger Index
WRAPUP 2-Daiichi Sankyo Q1 results jump, Takeda slides
* Daiichi quarterly profit jumps tenfold, Eisai up 30 pct
Read more on Reuters via Yahoo! Philippines News
Related posts:
- AstraZeneca weighs options after Canadian Court decision on Nexium
- AstraZeneca bloodthinner goes before U.S. experts
- AstraZeneca Wins Backing on Drug to Rival Plavix and Replace Aging Drugs
- Latest “nexium” News
- Latest Generic Drugs News
Tags: AstraZeneca, Brilinta, buyback, doubles, shines